Focused On-demand Library for Sulfate transporter

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P50443

UPID:
S26A2_HUMAN

ALTERNATIVE NAMES:
Diastrophic dysplasia protein; Solute carrier family 26 member 2

ALTERNATIVE UPACC:
P50443; A8K2U3; B2R6J1; Q6N051

BACKGROUND:
Sulfate transporter, known for its alternative names Diastrophic dysplasia protein and Solute carrier family 26 member 2, is integral to chondrocyte function. It ensures adequate sulfate levels for proteoglycan sulfation, crucial for cartilage health. This protein's ability to mediate anion exchange underpins its essential role in skeletal development and maintenance.

THERAPEUTIC SIGNIFICANCE:
The critical involvement of the Sulfate transporter in diseases such as Diastrophic dysplasia, Achondrogenesis 1B, Atelosteogenesis 2, and Multiple epiphyseal dysplasia 4 underscores its therapeutic potential. Exploring the mechanisms of this protein could unlock new pathways for treating these genetic disorders, significantly improving patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 966 of 8789